Background: Previously, we demonstrated similar human papillomavirus (HPV)16/18 vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination in a nonrandomized analysis of women who received a varying number of doses of the bivalent HPV16/18 vaccine. Here we extend data to seven years following initial vaccination. Methods: We evaluated HPV16/18-vaccinated women who received one (n = 134), two (n 0/1 = 193, n 0/6 = 79), or three doses (n = 2043) to a median of 6.9 years postvaccination. Cervical HPV DNA was measured with the SPF10- DEIA-LiPA PCR system; HPV16/18-specific antibody levels were measured using enzyme-linked immunosorbent assays (n = 486). Infection and immunological measures were compared across vaccine dose groups. Prevalent HPV infection at year 7 was also compared with an unvaccinated control group (UCG). All statistical tests were two-sided. Results: Among women in the three-dose, two-dose 0/6 , two-dose 0/1 , and one-dose groups, cumulative incident HPV16/18 infection rates (No. of events/No. of individuals) were 4.3% (88/2036, 95% confidence interval [CI] = 3.5% to 5.3%), 3.8% (3/78, 95% CI = 1.0% to 10.1%), 3.6% (7/192, 95% CI = 1.6% to 7.1%), and 1.5% (2/133, 95% CI = 0.3% to 4.9%; P = 1.00, .85, .17 comparing the two-dose 0/6 , two-dose 0/1 , and one-dose groups to the three-dose group, respectively). The prevalence of other carcinogenic and noncarcinogenic HPV types, excluding HPV16/18/31/33/45, were high and not statistically different among all dose groups, indicating that the low incidence of HPV16/18 in the one- and two-dose groups was not due to lack of exposure. At seven years, 100% of participants in all dose groups remained HPV16 and HPV18 seropositive. A non-statistically significant decrease in the geometric mean of the HPV16 antibody levels between years 4 and 7 was observed among women in the three-dose group: -10.8% (95% CI = -25.3% to 6.6%); two-dose (0/6 months) group: -17.3% (95% CI = -39.3% to 12.8%), two-dose (0/1 month) group: -6.9% (95% CI = -22.1% to 11.2%), and one-dose group: -5.5% (95% CI = -29.7% to 27.0%); results were similar for HPV18. Conclusions: At an average of seven years of follow-up, we observed similar low rates of HPV16/18 infections and slight, if any, decreases in HPV16/18 antibody levels by dose group. Published by Oxford University Press 2017. This work is written by US Government employees and is in the public domain in the US.
RCT Entities:
Background: Previously, we demonstrated similar human papillomavirus (HPV)16/18 vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination in a nonrandomized analysis of women who received a varying number of doses of the bivalent HPV16/18 vaccine. Here we extend data to seven years following initial vaccination. Methods: We evaluated HPV16/18-vaccinated women who received one (n = 134), two (n 0/1 = 193, n 0/6 = 79), or three doses (n = 2043) to a median of 6.9 years postvaccination. Cervical HPV DNA was measured with the SPF10- DEIA-LiPA PCR system; HPV16/18-specific antibody levels were measured using enzyme-linked immunosorbent assays (n = 486). Infection and immunological measures were compared across vaccine dose groups. Prevalent HPV infection at year 7 was also compared with an unvaccinated control group (UCG). All statistical tests were two-sided. Results: Among women in the three-dose, two-dose 0/6 , two-dose 0/1 , and one-dose groups, cumulative incident HPV16/18 infection rates (No. of events/No. of individuals) were 4.3% (88/2036, 95% confidence interval [CI] = 3.5% to 5.3%), 3.8% (3/78, 95% CI = 1.0% to 10.1%), 3.6% (7/192, 95% CI = 1.6% to 7.1%), and 1.5% (2/133, 95% CI = 0.3% to 4.9%; P = 1.00, .85, .17 comparing the two-dose 0/6 , two-dose 0/1 , and one-dose groups to the three-dose group, respectively). The prevalence of other carcinogenic and noncarcinogenic HPV types, excluding HPV16/18/31/33/45, were high and not statistically different among all dose groups, indicating that the low incidence of HPV16/18 in the one- and two-dose groups was not due to lack of exposure. At seven years, 100% of participants in all dose groups remained HPV16 and HPV18 seropositive. A non-statistically significant decrease in the geometric mean of the HPV16 antibody levels between years 4 and 7 was observed among women in the three-dose group: -10.8% (95% CI = -25.3% to 6.6%); two-dose (0/6 months) group: -17.3% (95% CI = -39.3% to 12.8%), two-dose (0/1 month) group: -6.9% (95% CI = -22.1% to 11.2%), and one-dose group: -5.5% (95% CI = -29.7% to 27.0%); results were similar for HPV18. Conclusions: At an average of seven years of follow-up, we observed similar low rates of HPV16/18 infections and slight, if any, decreases in HPV16/18 antibody levels by dose group. Published by Oxford University Press 2017. This work is written by US Government employees and is in the public domain in the US.
Authors: B Kleter; L J van Doorn; L Schrauwen; A Molijn; S Sastrowijoto; J ter Schegget; J Lindeman; B ter Harmsel; M Burger; W Quint Journal: J Clin Microbiol Date: 1999-08 Impact factor: 5.948
Authors: Francis J Dessy; Sandra L Giannini; Catherine A Bougelet; Troy J Kemp; Marie-Pierre M David; Sylviane M Poncelet; Ligia A Pinto; Martine A Wettendorff Journal: Hum Vaccin Date: 2008-11-11
Authors: Simon R M Dobson; Shelly McNeil; Marc Dionne; Meena Dawar; Gina Ogilvie; Mel Krajden; Chantal Sauvageau; David W Scheifele; Tobias R Kollmann; Scott A Halperin; Joanne M Langley; Julie A Bettinger; Joel Singer; Deborah Money; Dianne Miller; Monika Naus; Fawziah Marra; Eric Young Journal: JAMA Date: 2013-05-01 Impact factor: 56.272
Authors: Rolando Herrero; Allan Hildesheim; Ana C Rodríguez; Sholom Wacholder; Concepción Bratti; Diane Solomon; Paula González; Carolina Porras; Silvia Jiménez; Diego Guillen; Jorge Morales; Mario Alfaro; Jean Cyr; Kerrygrace Morrisey; Yenory Estrada; Bernal Cortés; Lidia Ana Morera; Enrique Freer; John Schussler; John Schiller; Douglas Lowy; Mark Schiffman Journal: Vaccine Date: 2008-07-18 Impact factor: 3.641
Authors: Mahboobeh Safaeian; Troy J Kemp; David Yuanji Pan; Carolina Porras; Ana Cecilia Rodriguez; Mark Schiffman; Bernal Cortes; Hormuzd Katki; Sholom Wacholder; John T Schiller; Paula Gonzalez; Kerri Penrose; Douglas R Lowy; Wim Quint; Leen-Jan van Doorn; Rolando Herrero; Allan Hildesheim; Ligia A Pinto Journal: Hum Vaccin Immunother Date: 2013-04-09 Impact factor: 3.452
Authors: Aimée R Kreimer; Ana Cecilia Rodriguez; Allan Hildesheim; Rolando Herrero; Carolina Porras; Mark Schiffman; Paula González; Diane Solomon; Silvia Jiménez; John T Schiller; Douglas R Lowy; Wim Quint; Mark E Sherman; John Schussler; Sholom Wacholder Journal: J Natl Cancer Inst Date: 2011-09-09 Impact factor: 13.506
Authors: Sabrina H Tsang; Partha Basu; Noemi Bender; Rolando Herrero; Troy J Kemp; Aimée R Kreimer; Martin Müller; Gitika Panicker; Michael Pawlita; Ligia A Pinto; Joshua N Sampson; Rengaswamy Sankaranarayanan; John Schussler; Peter Sehr; Monica S Sierra; Elizabeth R Unger; Tim Waterboer; Allan Hildesheim Journal: Vaccine Date: 2020-07-24 Impact factor: 3.641
Authors: Aimée R Kreimer; Joshua N Sampson; Carolina Porras; John T Schiller; Troy Kemp; Rolando Herrero; Sarah Wagner; Joseph Boland; John Schussler; Douglas R Lowy; Stephen Chanock; David Roberson; Mónica S Sierra; Sabrina H Tsang; Mark Schiffman; Ana Cecilia Rodriguez; Bernal Cortes; Mitchell H Gail; Allan Hildesheim; Paula Gonzalez; Ligia A Pinto Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506
Authors: Carolina Porras; Joshua N Sampson; Rolando Herrero; Mitchell H Gail; Bernal Cortés; Allan Hildesheim; Jean Cyr; Byron Romero; John T Schiller; Christian Montero; Ligia A Pinto; John Schussler; Karla Coronado; Mónica S Sierra; Jane J Kim; Catherine M Torres; Loretto Carvajal; Sarah Wagner; Nicole G Campos; Rebecca Ocampo; Troy J Kemp; Michael Zuniga; Douglas R Lowy; Carlos Avila; Stephen Chanock; Ariane Castrillo; Yenory Estrada; Gloriana Barrientos; Cindy Monge; María Y Oconitrillo; Aimée R Kreimer Journal: Vaccine Date: 2021-11-29 Impact factor: 3.641
Authors: Sabrina H Tsang; Joshua N Sampson; John Schussler; Carolina Porras; Sarah Wagner; Joseph Boland; Bernal Cortes; Douglas R Lowy; John T Schiller; Mark Schiffman; Troy J Kemp; Ana Cecilia Rodriguez; Wim Quint; Mitchell H Gail; Ligia A Pinto; Paula Gonzalez; Allan Hildesheim; Aimée R Kreimer; Rolando Herrero Journal: J Natl Cancer Inst Date: 2020-10-01 Impact factor: 13.506
Authors: Michelle B Shin; Gui Liu; Nelly Mugo; Patricia J Garcia; Darcy W Rao; Cara J Bayer; Linda O Eckert; Leeya F Pinder; Judith N Wasserheit; Ruanne V Barnabas Journal: Front Public Health Date: 2021-07-01